Summary
Celyad SA (Celyad), formerly Cardio3 BioSciences, is a biopharmaceutical company that focuses on the discovery and development of engineered cell therapies. The company offers C-Cure, a cell-based reparative therapy to treat heart failure; C-Cathez, an intraventricular injection catheter which is used in cardiac surgery operations; NKR-2, an autologous chimeric antigen receptor; and others. Its heart access technology is used for the treatment of various indications including mitral valve disorders and structural heart diseases. The company also offers pipeline products in the areas of immuno-oncology, cardiovascular and medical devices. It has a presence in Belgium and the US. Celyad is headquartered in Mont-Saint-Guibert, Belgium.
Celyad SA (CYAD) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Celyad SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Celyad SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Celyad SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Celyad SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Celyad SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Celyad SA, Medical Equipment, Deal Details 10
Venture Financing 10
Cardio3 BioSciences Raises US$9 Million In Series D Financing 10
Equity Offering 10
Celyad Raises USD80.1 Million in Public Offering of ADSs 10
Celyad Raises USD19.8 Million in Private Placement of Shares 12
Cardio3 BioSciences Raises USD35.5 Million in Private Placement of Shares 14
Cardio3 BioSciences Raises USD17 Million in Second Tranche of Private Placement of Shares 14
Cardio3 BioSciences Completes IPO For US$30.8 Million 15
Acquisition 17
Cardio3 BioSciences Acquires CorQuest Medical 17
Celyad SA - Key Competitors 19
Key Employees 20
Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 25, 2016: Celyad Reports First Half 2016 Financial Results and Operational Progress 22
Mar 31, 2016: Celyad reports 2015 Financial and Operating results 24
Corporate Communications 26
Jun 06, 2016: Celyad appoints Dr. David Gilham as Vice-President of Research & Development 26
Apr 06, 2016: Celyad appoints leading international Immuno-Oncology experts to Scientific Advisory Board 27
Feb 08, 2016: Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination Plan 28
Feb 03, 2016: Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs 29
Jan 04, 2016: Celyad announces the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise 30
Other Significant Developments 31
Nov 18, 2016: Celyad Announces Third Quarter 2016 Business Update 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List of Tables
Celyad SA, Medical Equipment, Key Facts, 2015 1
Celyad SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Celyad SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Celyad SA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Celyad SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Celyad SA, Deals By Market, 2011 to YTD 2017 8
Celyad SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cardio3 BioSciences Raises US$9 Million In Series D Financing 10
Celyad Raises USD80.1 Million in Public Offering of ADSs 10
Celyad Raises USD19.8 Million in Private Placement of Shares 12
Cardio3 BioSciences Raises USD35.5 Million in Private Placement of Shares 14
Cardio3 BioSciences Raises USD17 Million in Second Tranche of Private Placement of Shares 14
Cardio3 BioSciences Completes IPO For US$30.8 Million 15
Cardio3 BioSciences Acquires CorQuest Medical 17
Celyad SA, Key Competitors 19
Celyad SA, Key Employees 20
Celyad SA, Subsidiaries 21
List of Figures
Celyad SA, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Celyad SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Celyad SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Celyad SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Celyad SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Celyad SA, Medical Equipment, Deals by Type, 2011 to YTD 2017 6
Celyad SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Celyad SA, Medical Equipment, Deals by Market, 2011 to YTD 2017 8
